Alnylam Pharmaceuticals, Inc. (ALNY)
Market Cap | 57.03B |
Revenue (ttm) | 2.46B |
Net Income (ttm) | -319.09M |
Shares Out | 131.08M |
EPS (ttm) | -2.46 |
PE Ratio | n/a |
Forward PE | 122.57 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,152,674 |
Open | 429.33 |
Previous Close | 428.14 |
Day's Range | 425.81 - 436.77 |
52-Week Range | 205.87 - 436.77 |
Beta | 0.25 |
Analysts | Strong Buy |
Price Target | 401.92 (-7.63%) |
Earnings Date | Jul 31, 2025 |
About PYCR
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]
Financial Performance
In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for ALNY stock is "Strong Buy." The 12-month stock price target is $401.92, which is a decrease of -7.63% from the latest price.
News

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord...

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance
Alnylam Pharmaceuticals Inc. ALNY reported upbeat second-quarter earnings and 2025 guidance on Thursday.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Christine Regan Akinc - Chief Corporate Communications Officer Jeffrey V. Po...

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. ALNY continue to outperform market expectations. Amid a backdrop of growing demand fo...

Alnylam: Amvuttra Is Just Getting Started
Shares of Alnylam Pharmaceuticals, Inc. surged after the company reported strong second quarter results. The revenue and EPS beats were driven by the very strong U.S. launch of Amvuttra for the treatm...

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended J...

Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter end...

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?
Alnylam Pharmaceuticals ALNY is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure.

Alnylam Pharmaceuticals Names Garg R&D Chief
Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed E...

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted...

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman S...

Alnylam Issues 2024 Corporate Responsibility Report
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Gui...

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of ...

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship ...

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Secu...

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstre...

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Ma...

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for...

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter endi...

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 2...
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.